Stocks · News reference
Favorable, differentiated safety profile and durable single-agent clinical activity, including in heavily pretreated subjects with lung cancer remaining on treatment for over a yearOral weekly regimen (3 days on/4 days
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.50) by 14 percent. This is a 21.82 percent increase over losses of $(0.55) per share
Filed: 2026-08-12 AccNo: 0001193125-26-346859 Size: 435 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Presentations and DetailsOral Podium PresentationTitle: Acrivon Predictive Precision Proteomics (AP3): Next Generation Precision Medicine for Phosphoproteomics-Guided Drug DiscoveryPresenter: Lei Shi, Ph.D., Director